290 related articles for article (PubMed ID: 18829747)
1. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.
Grove J; Nielsen S; Zhong J; Bassendine MF; Drummer HE; Balfe P; McKeating JA
J Virol; 2008 Dec; 82(24):12020-9. PubMed ID: 18829747
[TBL] [Abstract][Full Text] [Related]
2. Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.
Cowton VM; Angus AGN; Cole SJ; Markopoulou CK; Owsianka A; Dunlop JI; Gardner DE; Krey T; Patel AH
J Virol; 2016 Aug; 90(16):7456-7468. PubMed ID: 27279607
[TBL] [Abstract][Full Text] [Related]
3. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity.
Grove J; Huby T; Stamataki Z; Vanwolleghem T; Meuleman P; Farquhar M; Schwarz A; Moreau M; Owen JS; Leroux-Roels G; Balfe P; McKeating JA
J Virol; 2007 Apr; 81(7):3162-9. PubMed ID: 17215280
[TBL] [Abstract][Full Text] [Related]
4. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.
Lavie M; Sarrazin S; Montserret R; Descamps V; Baumert TF; Duverlie G; Séron K; Penin F; Dubuisson J
J Virol; 2014 Sep; 88(18):10584-97. PubMed ID: 24990994
[TBL] [Abstract][Full Text] [Related]
5. A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.
Zuiani A; Chen K; Schwarz MC; White JP; Luca VC; Fremont DH; Wang D; Evans MJ; Diamond MS
J Virol; 2016 Dec; 90(23):10499-10512. PubMed ID: 27630236
[TBL] [Abstract][Full Text] [Related]
6. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.
Bitzegeio J; Bankwitz D; Hueging K; Haid S; Brohm C; Zeisel MB; Herrmann E; Iken M; Ott M; Baumert TF; Pietschmann T
PLoS Pathog; 2010 Jul; 6(7):e1000978. PubMed ID: 20617177
[TBL] [Abstract][Full Text] [Related]
7. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.
Bankwitz D; Vieyres G; Hueging K; Bitzegeio J; Doepke M; Chhatwal P; Haid S; Catanese MT; Zeisel MB; Nicosia A; Baumert TF; Kaderali L; Pietschmann T
J Virol; 2014 Nov; 88(21):12644-55. PubMed ID: 25142595
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement.
Chen Z; Zhu Y; Ren Y; Tong Y; Hua X; Zhu F; Huang L; Liu Y; Luo Y; Lu W; Zhao P; Qi Z
PLoS One; 2011 Apr; 6(4):e18933. PubMed ID: 21526201
[TBL] [Abstract][Full Text] [Related]
9. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.
Bartosch B; Vitelli A; Granier C; Goujon C; Dubuisson J; Pascale S; Scarselli E; Cortese R; Nicosia A; Cosset FL
J Biol Chem; 2003 Oct; 278(43):41624-30. PubMed ID: 12913001
[TBL] [Abstract][Full Text] [Related]
10. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
11. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.
Dreux M; Pietschmann T; Granier C; Voisset C; Ricard-Blum S; Mangeot PE; Keck Z; Foung S; Vu-Dac N; Dubuisson J; Bartenschlager R; Lavillette D; Cosset FL
J Biol Chem; 2006 Jul; 281(27):18285-95. PubMed ID: 16675450
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.
Krieger SE; Zeisel MB; Davis C; Thumann C; Harris HJ; Schnober EK; Mee C; Soulier E; Royer C; Lambotin M; Grunert F; Dao Thi VL; Dreux M; Cosset FL; McKeating JA; Schuster C; Baumert TF
Hepatology; 2010 Apr; 51(4):1144-57. PubMed ID: 20069648
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
[TBL] [Abstract][Full Text] [Related]
14. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission.
Catanese MT; Loureiro J; Jones CT; Dorner M; von Hahn T; Rice CM
J Virol; 2013 Aug; 87(15):8282-93. PubMed ID: 23698298
[TBL] [Abstract][Full Text] [Related]
15. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
16. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps.
Dao Thi VL; Granier C; Zeisel MB; Guérin M; Mancip J; Granio O; Penin F; Lavillette D; Bartenschlager R; Baumert TF; Cosset FL; Dreux M
J Biol Chem; 2012 Sep; 287(37):31242-57. PubMed ID: 22767607
[TBL] [Abstract][Full Text] [Related]
17. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.
Dreux M; Dao Thi VL; Fresquet J; Guérin M; Julia Z; Verney G; Durantel D; Zoulim F; Lavillette D; Cosset FL; Bartosch B
PLoS Pathog; 2009 Feb; 5(2):e1000310. PubMed ID: 19229312
[TBL] [Abstract][Full Text] [Related]
18. Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins.
Koutsoudakis G; Dragun J; Pérez-Del-Pulgar S; Coto-Llerena M; Mensa L; Crespo G; González P; Navasa M; Forns X
PLoS One; 2012; 7(12):e52651. PubMed ID: 23300734
[TBL] [Abstract][Full Text] [Related]
19. Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection.
Tong Y; Zhu Y; Xia X; Liu Y; Feng Y; Hua X; Chen Z; Ding H; Gao L; Wang Y; Feitelson MA; Zhao P; Qi ZT
J Virol; 2011 Mar; 85(6):2793-802. PubMed ID: 21177818
[TBL] [Abstract][Full Text] [Related]
20. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.
Wünschmann S; Medh JD; Klinzmann D; Schmidt WN; Stapleton JT
J Virol; 2000 Nov; 74(21):10055-62. PubMed ID: 11024134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
